NCT03377530 (BACILLUS) is a clinical trial of Ways to prevent these infections. in Bacillus Cereus Infection, sponsored by Hôpital NOVO.

Who is sponsoring NCT03377530?

NCT03377530 is sponsored by Hôpital NOVO.

What drugs are being tested in NCT03377530?

Interventions in NCT03377530: Ways to prevent these infections..

What condition does NCT03377530 study?

NCT03377530 studies Bacillus Cereus Infection.

Is NCT03377530 still recruiting?

NCT03377530 is currently completed. Last updated 30 July 2019.

Last reviewed 2019-07-30 · How we verify

NCT03377530: BACILLUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contamination of Bacillus Species Sepsis.

Completed Last updated 30 July 2019

What this trial tests

trial testing Ways to prevent these infections. in Bacillus Cereus Infection in 11 participants. Completed in 31 August 2016.

Timeline

1 January 2008

Primary endpoint
31 August 2016

31 August 2016

Quick facts

Lead sponsor	Hôpital NOVO
Status	Completed
Study type	OBSERVATIONAL
Enrollment	11
Start date	1 January 2008
Primary completion	31 August 2016
Estimated completion	31 August 2016

Drugs / interventions tested

Ways to prevent these infections.

Conditions studied

Bacillus Cereus Infection — all drugs for Bacillus Cereus Infection →

Sponsor

Hôpital NOVO — full company profile →

Who can join

Under 28 Days, any sex, with Bacillus Cereus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bacillus species are ubiquitous gram-positive spore-forming organisms. They rarely cause disease in the immunocompetent and are more frequently isolated as a culture contaminant. However, Bacillus Species can cause severe systemic infections in immunocompromised patients including preterm infants. The purpose of this study is to identify the risk factors of these infections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hôpital NOVO trials

Trials by the same sponsor.

NCT07394478 — Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica · not yet recruiting
NCT07412340 — Disarticulation Septoplasty Versus Classical Way · not yet recruiting
NCT07298070 — Functional and Aesthetic Outcomes Following Lower Lip Reconstruction · not yet recruiting
NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03377530 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hôpital NOVO
Last refreshed: 30 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03377530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing